Chiesi USA Inc (Chiesi USA) is a specialty pharmaceutical company that acquires, develops and commercializes proprietary products for the hospital, niche respiratory, and related specialty markets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The is engaged in a balanced and targeted pipeline of research and development initiatives, focusing on respiratory, neonatology, and special care. In the respiratory area, the company is expanding R&D activities to address therapeutic needs in asthma, chronic obstructive pulmonary disease, and other respiratory diseases, with a development pipeline that includes new molecular entities such as innovative anti-inflammatory, bronchodilator, and antifibrotic molecules. In neonatology, the company is advancing programs for devastating respiratory diseases and conditions of the newborn. In special care, the focus is on cardiovascular conditions, with the anti-thrombotic candidate CUSA 081 in an advanced stage of development. The R&D units of Chiesi are focused on three main areas: respiratory, neonatology, and special care. The respiratory unit serves as the hub of Research & Development activities, addressing therapeutic needs in respiratory diseases. The neonatology unit is dedicated to research and development for respiratory diseases and conditions affecting newborns. The special care unit focuses on cardiovascular conditions, particularly the development of anti-thrombotic candidates.